Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Ovarian Neoplasms 13Fallopian Tube Neoplasms 12Colorectal Neoplasms 8Melanoma 6Glioblastoma 5Uterine Cervical Neoplasms 4Gliosarcoma 4Carcinoma, Renal Cell 4Carcinoma, Non-Small-Cell Lung 4Brenner Tumor 4Breast Neoplasms 4Triple Negative Breast Neoplasms 3Squamous Cell Carcinoma of Head and Neck 3Recurrent Squamous Cell Lung Carcinoma 3Rectal Neoplasms 3Prostatic Neoplasms 3Oligodendroglioma 3Colonic Neoplasms 3Brain Neoplasms 3Uveal Melanoma 2Spinal Cord Neoplasms 2Pancreatic Neoplasms 2Medulloblastoma 2Lung Neoplasms 2Glioma 2Carcinoma, Hepatocellular 2Astrocytoma 2Vulvar Neoplasms 1Virus Diseases 1Vipoma 1

Interventions

human papillomavirus vaccine, L1 type 16, 18 3Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18 2ledipasvir, sofosbuvir drug combination 1hepatitis C immune globulin, human 1halofantrine 1VP-102 1Therapies, Investigational 1Rituximab 1Papillomavirus Vaccines 1Kidney Transplantation 1Ipilimumab 1Influenza Vaccines 1Immunoglobulin G 1Imiquimod 1Gels 1Drug Therapy 1Cantharidin 1Bevacizumab 1Antibodies, Monoclonal 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Virus Diseases × Immunoglobulin G × Clear all
NCT01804829 2017-03-15

Civacir® Polyclonal Immune Globulin (IgG) to Prevent Hepatitis C Virus (HCV) Recurrence in Liver Transplant Patients.

Biotest Pharmaceuticals Corporation

Phase 3 Completed
80 enrolled
Gastrointestinal

Hepatitis, Viral, Human, Hepatitis C, Carcinoma, Hepatocellular, Liver Cirrhosis, Virus Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡